Ergoteles’s Agilon Health AGL Stock Holding History

Ergoteles’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-799	Closed	-$474K	–	1010
2023 Q1	$474K	Buy	+799	New	+$448K	0.02%	751
2022 Q3	–	Sell	-1,483	Closed	-$809K	–	1507
2022 Q2	$809K	Buy	+1,483	New	+$750K	0.02%	638
2021 Q4	–	Sell	-7,927	Closed	-$5.19M	–	1207
2021 Q3	$5.19M	Buy	+7,927	New	+$6.77M	0.19%	143

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ergoteles's AGL Position: Q2 2023 in Review

Ergoteles sold out of Agilon Health (AGL) in Q2 2023, closing a stake of 799 shares — an estimated $474K sold.

Ergoteles first reported a position in AGL in Q3 2021 and held it in 3 quarters. The position peaked at $5.19M in Q3 2021. 185 funds tracked by Wall St. Rank hold AGL as of Q2 2023.

Ergoteles reported no remaining Agilon Health position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 799 Agilon Health shares in Q2 2023, an estimated $474K.
Ergoteles first reported a position in Agilon Health in Q3 2021 and held it in 3 quarters.
Ergoteles's Agilon Health position peaked at $5.19M in Q3 2021.
185 funds tracked by Wall St. Rank held Agilon Health as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.